Please login to the form below

Not currently logged in
Email:
Password:

GSK splits media account between two agencies

GroupM and Omnicom are the winners in GSK’s latest consolidation

GSK GlaxoSmithKline house

One year after the September 2012 appointment of vice president and head of global media Sam Singh, GSK has completed a review of its global media planning and buying account.

Singh's remit on joining GSK was to develop a new approach to media, and this review sees the healthcare and pharma giant again streamlining its media buying. GSK's global account, worth an estimated £1bn, is to be split between Group M and Omnicom Media Group (OMG).

OMG agency PHD will retain the US business, worth in the region of £890m, and will also run the Canadian and West African markets.
GroupM, part of WPP, will cover the rest of the world, with the exception of Japan, which will be managed by Dentsu, and the UK, where MediaCom is expected to retain GSK's £60m account.

OMG and Group M will split responsibility for global category-planning for consumer healthcare, operating out of London, Singapore and Parsippanny, New Jersey.

The main losers in the consolidation are Publicis Group's Starcom and Carat, who formerly worked alongside PHD and GroupM.

"The decision to consolidate our media investment with two network partners is based on various factors including simplicity and speedier deployment of best practices,” said Singh. “We believe this sets us up with a fit for purpose media system into the future.

"We continue to hold the outgoing agencies, Starcom and Carat, in the highest of regard. They have consistently exhibited high levels of professionalism and we wish them all the very best,” he added.

Article by
Tara Craig

5th September 2013

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics